Providing scientific and immunological mechanism of action due diligence for a big pharma client


A major pharma company needed scientific and immunology due diligence support on a novel cyclic peptide, targeting the complement cascade system.


We reviewed the scientific and mechanistic experiments underpinning the clinical program to understand the risk around a clinical study failing an efficacy endpoint. The research program and resultant data demonstrated a compelling mechanistic rationale to treat the disease and we recommend that our client should proceed from the standpoint of an immunological mechanism of action and scientific merit.

Share on FacebookShare on Google+Tweet about this on TwitterShare on LinkedIn

Stay in touch